Examples of using 诺和诺德 in Chinese and their translations into English
{-}
-
Political
-
Ecclesiastic
-
Programming
改变糖尿病是诺和诺德针对全球糖尿病挑战所做出的承诺。
在诺和诺德工作在诺和诺德，您的技能、奉献精神和抱负将帮助我们让生活变得更好。
At Novo Nordisk, your skills, dedication and ambition help us improve lives.在诺和诺德，你的技能、奉献精神和报复将帮助大家让生活变得更好。
At Novo Nordisk, your skills, dedication and ambition help us improve lives.诺和诺德在未来几年还将把胰岛素给药数据与DexcomCGM数据整合在一起。
Novo Nordisk will incorporate insulin dosing data with Dexcom CGM data in the coming years.诺和诺德将开展进一步合作，以针对其它严重慢性疾病研发干细胞治疗。
Novo Nordisk has an ambition to pursue further collaborations to develop stem cell-based therapies for other serious chronic diseases.诺和诺德在未来几年还将把胰岛素给药数据与DexcomCGM数据整合在一起。
Novo Nordisk will also reportedly integrate insulin dosing data with Dexcom CGM data in the coming years.诺和诺德蓝海战略改变了行业的面貌，并将公司从胰岛素生产商转变为糖尿病治疗公司。
Novo Nordisk's blue ocean strategy shifted the industry landscape and transformed the company from an insulin producer to a diabetes care company.与诺和诺德的血友病组合一致，研究合作最初将集中于纠正fviii凝血因子缺乏症，具有探索其他治疗靶点的潜力。
Aligned with Novo Nordisk's hemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets.诺和诺德在2017年的糖尿病市场份额为27%，按价值计算，它当之无愧是最大的糖尿病药物制造商。
Novo Nordisk's diabetes market share was 27% in 2017, which makes it the biggest diabetes-drug maker in terms of market value.根据由糖尿病药物制造企业诺和诺德资助的一项研究，从2015年到2030年，糖尿病治疗支出将从4080亿美元增加到6220亿美元。
According to a study financed by diabetes-drug maker Novo Nordisk, spending on diabetes treatment will increase from $408 billion to $622 billion between 2015 and 2030.诺和诺德基础代谢基金会馆研究.
The Novo Nordisk Foundation Center for Basic Metabolic Research.诺和诺德礼来.
诺和诺德从1923年以来就一直致力于改变糖尿病。
At Novo Nordisk, we have been changing diabetes since 1923.诺和诺德是世界上加入WWF拯救气候行动的第十家公司。
Novo Nordisk was the 10th company in the world to join the WWF Climate Savers initiative…”.此外，诺和诺德车队拥有糖尿病社区和专业自行车运动最大的社交媒体追随者。
Additionally, Team Novo Nordisk has the largest social media following for both the diabetes community and professional cycling.近日，诺和诺德宣布增加对干细胞治疗的投入，并将对1型糖尿病的关注扩展到其它严重慢性疾病领域。
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases.诺和诺德计划在2019年第4季度使美国2型糖尿病患者能够用上Rybelsus®。
Novo Nordisk plans to make Rybelsus® available to adults with type 2 diabetes in the US in the fourth quarter of 2019.其中，诺和诺德占据了总市场份额的25％以上。
Among them, Novo Nordisk took over 25% of the market share in total.由于第三方知识产权协议，诺和诺德将无法在2020年之前在美国推出Esperoct。
However due to third-party intellectual property agreements, Novo Nordisk will be unable to launch Esperoct before 2020 in the U.S. A.引用诺和诺德首席执行官拉尔斯·索伦森的话：“从长远来看，社会和环境问题已成为财务问题。
To quote Novo Nordisk CEO Lars Sørensen,“In the long term, social and environmental issues become financial issues.”.
